| Literature DB >> 26334483 |
Jessica D Sims1, Jae Youn Hwang2, Shawn Wagner3, Felix Alonso-Valenteen1, Chris Hanson1, Jan Michael Taguiam1, Richard Polo1, Ira Harutyunyan4, Gevorg Karapetyan4, Karn Sorasaenee4, Ahmed Ibrahim5, Eduardo Marban6, Rex Moats4, Harry B Gray7, Zeev Gross8, Lali K Medina-Kauwe9.
Abstract
Water-soluble corroles with inherent fluorescence can form stable self-assemblies with tumor-targeted cell penetration proteins, and have been explored as agents for optical imaging and photosensitization of tumors in pre-clinical studies. However, the limited tissue-depth of excitation wavelengths limits their clinical applicability. To examine their utility in more clinically-relevant imaging and therapeutic modalities, here we have explored the use of corroles as contrast enhancing agents for magnetic resonance imaging (MRI), and evaluated their potential for tumor-selective delivery when encapsulated by a tumor-targeted polypeptide. We have found that a manganese-metallated corrole exhibits significant T1 relaxation shortening and MRI contrast enhancement that is blocked by particle formation in solution but yields considerable MRI contrast after tissue uptake. Cell entry but not low pH enables this. Additionally, the corrole elicited tumor-toxicity through the loss of mitochondrial membrane potential and cytoskeletal breakdown when delivered by the targeted polypeptide. The protein-corrole particle (which we call HerMn) exhibited improved therapeutic efficacy compared to current targeted therapies used in the clinic. Taken together with its tumor-preferential biodistribution, our findings indicate that HerMn can facilitate tumor-targeted toxicity after systemic delivery and tumor-selective MR imaging activatable by internalization.Entities:
Keywords: Corrole; MRI; Manganese; Nanoparticle; Tumor-targeting
Mesh:
Substances:
Year: 2015 PMID: 26334483 PMCID: PMC4623877 DOI: 10.1016/j.jconrel.2015.08.046
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776